Journal Update Archive
CME credits for these Journal Updates have now expired but you may still view them for information.
Click here to return to the current journals.
December 08
This Section is eligible for 1.0 AMA PRA Category 1 Credit(s). Please read all articles in the section before applying for CME credits.
- The risk of developing Crohn's disease after an appendectomy: A meta-analysis
Kaplan GG, Jackson T, Sands BE, et al. - Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease
van Limbergen J, Russell RK, Drummond HE, et al. - Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
Barrett JC, Hansoul S, Nicolae DL, et al. - A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease
Sandborn WJ, Feagan BG, Fedorak RN, et al. - Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: A controlled randomized trial
D’Haens GR, Vermeire S, van Assche G, et al.
September 08
This Section is eligible for 1.0 AMA PRA Category 1 Credit(s). Please read all articles in the section before applying for CME credits.
- Immunosuppressant medications and mortality in inflammatory bowel disease
Lewis JD, Gelfand JM, Troxel AB, et al. - The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease
Moss AC, Fernandez-Becker N, Jo Kim K, Cury D, Cheifetz AS. - Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: Meta analysis of placebo-controlled trials
Peyrin-Biroulet L, Deltenre P, De Suray N, et al. - Small-bowel imaging in Crohn's disease: A prospective,
blinded, 4 way comparison trial
Solem CA, Loftus Jr. EV, Fletcher JG, et al. - Risk factors for opportunistic infections in patients with inflammatory bowel disease
Toruner M, Loftus EV Jr., Harmsen WS, et al.
June 08
This Section is eligible for 1.0 AMA PRA Category 1 Credit(s). Please read all articles in the section before applying for CME credits.
- A prospective multivariate analysis of clinical factors associated with pouchitis after ileal pouch–anal anastomosis
Fleshner P, Ippoliti A, Dubinsky M, et al. - Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: An open randomised trial
D’Haens G, Baert F, van Assche G, et al. - High frequency of early colorectal cancer in inflammatory bowel disease
Lutgens MW, Vleggaar FP, Schipper MEI, et al. - Higher incidence of abnormal Pap smears in women with inflammatory bowel disease
Kane S, Khatibi B, Reddy D. - Rosiglitazone for active ulcerative colitis: A randomized placebo-controlled trial
Lewis JD, Lichtenstein GR, Deren JJ, et al; Rosiglitazone for Ulcerative Colitis Study Group.
March 08
This Section is eligible for 1.0 AMA PRA Category 1 Credit(s). Please read all articles in the section before applying for CME credits.
- A pilot study of intrastricture steroid versus placebo injection after balloon dilatation of Crohn's strictures
East JE, Brooker JC, Rutter MD, Saunders BP. - The incidence of arterial thromboembolic diseases in inflammatory bowel disease: A population-based study
Bernstein CN, Wajda A, Blanchard JF. - Gender differences in presentation and course of disease in pediatric patients with Crohn's disease.
Gupta N, Bostrom AG, Kirschner BS, et al. - Laparoscopy or conventional open surgery for patients with ileocolonic Crohn's disease? A prospective study
Fichera A, Peng SL, Elisseou NM, et al. - Mortality by medication use among patients with inflammatory bowel disease, 1996–2003
Hutfless SM, Weng X, Lui L, et al. - Diagnostic yield of capsule endoscopy in ulcerative colitis and inflammatory bowel disease of unclassified type (IBDU)
Mehdizadeh S, Chen G, Enayati PJ, et al.
December 07
This Section is eligible for 1.75 AMA PRA Category 1 Credit(s). Please read all articles in the section before applying for CME credits.
- Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease
Vermeire S, Noman M, Van Assche G, et al. - Crohn's disease patients' risk–benefit preferences: Serious adverse event risks versus treatment efficacy
Johnson FR, Özdemir S, Mansfield C, et al. - Quantifying exposure to diagnostic medical radiation in patients with
inflammatory bowel disease: Are we contributing to malignancy?
Newnham E, Hawkes E, Surender A, et al. - Vertebral fractures and role of low bone mineral density in Crohn's disease
Siffledeen JS, Siminoski K, Jen H, Fedorak RN. - Thiopurine-induced liver injury in patients with inflammatory bowel disease: A systematic review
Gisbert JP, González-Lama Y, Maté J. - Antibiotics in Crohn's Disease Study Group. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease
Selby W, Pavli P, Crotty B, et al. - Utility of magnetic resonance imaging in small bowel Crohn’s disease
Martin DR, Lauenstein T, Sitaraman SV.
October 07
This Section is eligible for 1.0 AMA PRA Category 1 Credit(s). Please read all articles in the section before applying for CME credits.
- Mucosal T-cell immunoregulation varies in early and late Crohn's disease
Kugathasan S, Saubermann L, Smith L, et al. - CT enterography for Crohn's disease: Accurate preoperative diagnostic imaging
Vogel J, da Luz Moreira A, Baker M, et al. - Mucosal healing in inflammatory bowel disease: Results for a Norwegian population-based cohort
Frøslie KF, Jahnsen J, Moum BA, et al. - Natalizumab for the treatment of active Crohn's disease: Results of the ENCORE trial
Targan SR, Feagan BG, Fedorak RN, et al.
August 07
This Section is eligible for 4.25 AMA PRA Category 1 Credit(s). Please read all articles in the section before applying for CME credits.
- Predictors of early response to infliximab in patients with ulcerative colitis
Ferrante F, Vermeire S, Katsanos KH, et al. - Differentiating ulcerative colitis from Crohn’s disease in children and young adults: Report of a Working Group of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition and the Crohn’s and Colitis Foundation of America.
Working Group of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition and the Crohn's and Colitis Foundation of America - Predicting a change in diagnosis from ulcerative colitis to Crohn’s disease: A nested, case-control study.
Melmed GY, Elashoff R, Chen GC, et al. - Certolizumab pegol for the treatment of Crohn’s disease.
Sandborn WJ, Feagan BG, Stoinov S, et al, for the PRECISE 1 Study Investigators - Maintenance therapy with certolizumab pegol for Crohn’s disease (PRECISE 2).
Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al, for the PRECISE 2 Study Investigators - Adalimumab induction therapy for Crohn’s disease previously treated with infliximab: A randomized trial (GAIN).
Sandborn WJ, Rutgeerts P, Enns R, et al.
June 07
This Section is eligible for 60 minutes of CME credit. All articles in the Section must be completed before applying for CME credit.
- Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: The CHARM trial.
Colombel JF, Sandborn WJ, Rutgeerts P, et al. - Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children.
Hyams J, Crandall W, Kugathasan S, REACH Study Group, et al. - Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients.
Matsuoka K, Iwao Y, Mori T, et al. - Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine.
Sparrow MP, Hande SA, Friedman S, et al.
